Cocrystal Pharma (COCP) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Conservation Environment Environmental Materials Nature Offset Oil Package Packaging Pandemic Raw Materials Regenerative Waste Access Black Community Customer Cyber Death Diversity Drug Pricing Employee Engagement Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injuries Injury Privacy Product Quality Recall Recruit Reimbursement Retention Safety Satisfaction Skill Skills Social Stakeholder Supplier Supply Chain Training Union Volunteer Workers Workforce Workplace Safety Anti-corruption Assessment Assurance Audit Board Oversight Bonus Chronic Class Action Lawsuit Classified Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Materiality Oversee Oversight Plaintiff Proxy Contest Purpose R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Strategy Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 18, 2022, the 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2022 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1); (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (Proposal 2); (iii) approval of an amendment to the Certificate of Incorporation of the Company to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio to be determined by the Board of Directors within a range of one-for-four through one-for-12 (Proposal 3); and (iv) approval of an adjournment of the 2022 Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote at the 2022 Annual Meeting, all as described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2022.

Set forth below are the voting results on each matter submitted to the stockholders at the 2022 Annual Meeting.

Proposal 1. The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next annual meeting of stockholders:

Nominee
Mr. Roger Kornberg	36,205,765	11,524,660	19,336,908
Dr. Phillip Frost	34,778,872	12,951,553	19,336,908
Mr. Steven Rubin	28,379,767	19,350,658	19,336,908
Dr. Anthony Japour	26,490,380	21,240,045	19,336,908
Mr. Richard C. Pfenniger, Jr.	32,390,459	15,339,966	19,336,908

Proposal 2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

Votes For				Votes Against				Abstentions
	55,742,618				4,848,473				6,476,242

Proposal 3. The Company’s stockholders voted to approve an amendment to the Certificate of Incorporation of the Company to effect a reverse stock split of all outstanding shares of our common stock at a ratio to be determined by the Board of Directors within a range of one-for-four through one-for-12.

Votes For				Votes Against				Abstentions
	55,621,903				11,019,514				425,916

As there were sufficient votes to approve proposals 1 through 3, proposal 4 was moot.